These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 3387715)
1. Planning the size of survival time clinical trials with allowance for stratification. Moussa MA Stat Med; 1988 May; 7(5):559-69. PubMed ID: 3387715 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Lachin JM; Foulkes MA Biometrics; 1986 Sep; 42(3):507-19. PubMed ID: 3567285 [TBL] [Abstract][Full Text] [Related]
3. Investigating maximum power losses in survival studies with nonstratified randomization. Palta M Biometrics; 1985 Jun; 41(2):497-504. PubMed ID: 4027324 [TBL] [Abstract][Full Text] [Related]
4. Duration of accrual and follow-up for two-stage clinical trials. Case LD; Morgan TM Lifetime Data Anal; 2001 Mar; 7(1):21-37. PubMed ID: 11280845 [TBL] [Abstract][Full Text] [Related]
5. Sample size considerations for studies comparing survival curves using historical controls. Dixon DO; Simon R J Clin Epidemiol; 1988; 41(12):1209-13. PubMed ID: 3062140 [TBL] [Abstract][Full Text] [Related]
6. Determining the duration of comparative clinical trials while allowing for cure. Sposto R; Sather HN J Chronic Dis; 1985; 38(8):683-90. PubMed ID: 4019705 [TBL] [Abstract][Full Text] [Related]
7. Imbalance in treatment assignments in stratified blocked randomization. Hallstrom A; Davis K Control Clin Trials; 1988 Dec; 9(4):375-82. PubMed ID: 3203527 [TBL] [Abstract][Full Text] [Related]
8. The effect of unbalanced randomization on the progressively censored Savage test. Lesser ML Stat Med; 1982; 1(3):277-80. PubMed ID: 7187100 [TBL] [Abstract][Full Text] [Related]
9. Accrual by groups in trials with discrete-time survival endpoints. Jóźwiak K; Moerbeek M Clin Trials; 2013 Feb; 10(1):32-42. PubMed ID: 23203992 [TBL] [Abstract][Full Text] [Related]
10. Planning the size of clinical trials with allowance for patient noncompliance. Moussa MA Methods Inf Med; 1990 Jul; 29(3):243-6. PubMed ID: 2215266 [TBL] [Abstract][Full Text] [Related]
11. Sample size determination for comparing several survival curves with unequal allocations. Halabi S; Singh B Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409 [TBL] [Abstract][Full Text] [Related]
12. Sample size: when is enough enough? Kraemer HC Am J Med Sci; 1988 Nov; 296(5):360-3. PubMed ID: 3195627 [No Abstract] [Full Text] [Related]
13. Exact, conditional, and predictive power in planning clinical trials. Moussa MA Control Clin Trials; 1989 Dec; 10(4):378-85. PubMed ID: 2691205 [TBL] [Abstract][Full Text] [Related]
14. Design of Phase II cancer trials evaluating survival probabilities. Case LD; Morgan TM BMC Med Res Methodol; 2003 Apr; 3():6. PubMed ID: 12697051 [TBL] [Abstract][Full Text] [Related]
15. Optimal two-stage designs for clinical trials with binary response. Thall PF; Simon R; Ellenberg SS; Shrager R Stat Med; 1988 May; 7(5):571-9. PubMed ID: 3387716 [TBL] [Abstract][Full Text] [Related]
16. Sample size calculation for weighted rank tests comparing survival distributions under cluster randomization: a simulation method. Jung SH J Biopharm Stat; 2007; 17(5):839-49. PubMed ID: 17885869 [TBL] [Abstract][Full Text] [Related]
18. Early stopping in the two-sample problem for bounded random variables. DeMets DL; Halperin M Control Clin Trials; 1982 Mar; 3(1):1-11. PubMed ID: 7067469 [TBL] [Abstract][Full Text] [Related]
19. The crossover experiment for clinical trials. Brown BW Biometrics; 1980 Mar; 36(1):69-79. PubMed ID: 7370374 [TBL] [Abstract][Full Text] [Related]
20. Nonparametric estimation of duration of accrual and total study length for clinical trials. Morgan TM Biometrics; 1987 Dec; 43(4):903-12. PubMed ID: 3427175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]